Literature DB >> 27693981

Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment.

Roxanne Gaspersz1, Femke Lamers2, Justine M Kent3, Aartjan T F Beekman2, Johannes H Smit2, Albert M van Hemert4, Robert A Schoevers5, Brenda W J H Penninx6.   

Abstract

Evidence has shown that the DSM-5 anxious distress specifier captures a clinically valid construct that predicts a worse clinical course. Although of importance for treatment planning and monitoring, however, the specifier's ability to predict treatment outcome is unknown. This is the first study to examine the ability of the DSM-5 anxious distress specifier to predict treatment response and side effects in depressed patients who recently initiated antidepressant treatment. Patients were from the Netherlands Study of Depression and Anxiety, an ongoing longitudinal cohort study. Baseline, 1-year and 2-year follow-up data were used from 149 patients (18-65 years) with current Major Depressive Disorder (MDD) who recently started adequately dosed antidepressant medication. Five self-report items were used to construct the DSM-5 anxious distress specifier. Treatment outcomes were depression severity after 1 year and 2 years, remission of MDD after 2 years and antidepressant side effects during treatment. For comparison, analyses were repeated for comorbid DSM-IV-based anxiety disorders as a predictor. In depressed patients who received antidepressant treatment, the anxious distress specifier (prevalence = 59.1%) significantly predicted higher severity (1 year: B = 1.94, P = 0.001; 2 years: B = 1.63, P = 0.001), lower remission rates (OR = 0.44, P = 0.0496) and greater frequency of side effects (≥4 vs. 0: OR = 2.74, P = 0.061). In contrast, the presence of comorbid anxiety disorders did not predict these treatment outcomes. The anxious distress specifier significantly predicts poorer treatment outcomes as shown by higher depression severity, lower remission rates, and greater frequency of antidepressant side effects in patients with MDD on adequate antidepressant treatment. Therefore, this simple 5-item specifier is of potential great clinical usefulness for treatment planning and monitoring in depressed patients. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety disorders; Anxious distress; DSM-5 anxious distress specifier; Epidemiology; Major depressive disorder; Treatment response

Mesh:

Substances:

Year:  2016        PMID: 27693981     DOI: 10.1016/j.jpsychires.2016.09.018

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  14 in total

1.  Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.

Authors:  Robert M Anthenelli; Michael Gaffney; Neal L Benowitz; Robert West; Thomas McRae; Cristina Russ; David Lawrence; Lisa St Aubin; Alok Krishen; A Eden Evins
Journal:  J Gen Intern Med       Date:  2019-03-07       Impact factor: 5.128

2.  Anxious depression as a clinically relevant subtype of pediatric major depressive disorder.

Authors:  Isabelle Häberling; Noemi Baumgartner; Sophie Emery; Paola Keller; Michael Strumberger; Kristin Nalani; Klaus Schmeck; Suzanne Erb; Silke Bachmann; Lars Wöckel; Ulrich Müller-Knapp; Brigitte Contin-Waldvogel; Bruno Rhiner; Susanne Walitza; Gregor Berger
Journal:  J Neural Transm (Vienna)       Date:  2019-08-27       Impact factor: 3.575

3.  Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States.

Authors:  Deborah S Hasin; Aaron L Sarvet; Jacquelyn L Meyers; Tulshi D Saha; W June Ruan; Malka Stohl; Bridget F Grant
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

4.  The prognosis and changes of regional brain gray matter volume in MDD with gastrointestinal symptoms.

Authors:  Penghong Liu; Gaizhi Li; Aixia Zhang; Ning Sun; Lijun Kang; Chunxia Yang; Yanfang Wang; Kerang Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-09       Impact factor: 2.570

5.  The Relationship Between Depression Symptoms and Anxiety Symptoms During Acute ECT for Patients With Major Depressive Disorder.

Authors:  Chun-Jen Huang; Ching-Hua Lin; Jyh-I Wu; Wei-Cheng Yang
Journal:  Int J Neuropsychopharmacol       Date:  2019-10-01       Impact factor: 5.176

6.  Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables.

Authors:  Giampaolo Perna; Alessandra Alciati; Silvia Daccò; Massimiliano Grassi; Daniela Caldirola
Journal:  Psychiatry Investig       Date:  2020-03-12       Impact factor: 2.505

7.  Mapping the Presence of Anxiety Symptoms in Adults With Major Depressive Disorder.

Authors:  Fenfen Ge; Jingwen Jiang; Yue Wang; Mentong Wan; Wei Zhang
Journal:  Front Psychiatry       Date:  2021-05-19       Impact factor: 4.157

8.  The role of anxious distress in immune dysregulation in patients with major depressive disorder.

Authors:  Roxanne Gaspersz; Femke Lamers; Gayle Wittenberg; Aartjan T F Beekman; Albert M van Hemert; Robert A Schoevers; Brenda W J H Penninx
Journal:  Transl Psychiatry       Date:  2017-12-08       Impact factor: 6.222

9.  Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults.

Authors:  Philip E Polychroniou; Helen S Mayberg; W Edward Craighead; Jeffrey J Rakofsky; Vivianne Aponte Rivera; Ebrahim Haroon; Boadie W Dunlop
Journal:  Behav Sci (Basel)       Date:  2018-07-17

10.  Anxious distress in depressed outpatients: Prevalence, comorbidity, and incremental validity.

Authors:  Anthony J Rosellini; Michelle L Bourgeois; Jeannette Correa; Esther S Tung; Svetlana Goncharenko; Timothy A Brown
Journal:  J Psychiatr Res       Date:  2018-05-08       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.